Molecular Cytogenetics Market is Anticipated to Witness High Growth Owing to Rising Prevalence of Cancer
Molecular cytogenetics is a technique that combines molecular biology and cytogenetics to study chromosomes and identify genetic abnormalities at a molecular level. It allows the visualization of genetic materials like DNA sequences through techniques like fluorescence in situ hybridization (FISH). The global molecular cytogenetics market is majorly driven by the rising incidence of genetic abnormalities and various types of cancers. Molecular cytogenetics finds widespread application in detecting chromosomal aberrations in cancer, which helps in clinical diagnosis and prognosis. It helps identify specific genetic mutations related to cancer progression and select targeted therapy.
The global molecular cytogenetics market size is estimated to be valued at US$
4851.54 Mn in 2024 and is expected to exhibit a CAGR of 5.0% over the forecast period of 2024 to 2030.
Key Takeaways
Key players operating in the molecular
cytogenetics market size are UIC, Inc., Shimadzu Corporation, ELTRA
GmbH, Xylem Inc., Skalar Analytical B.V.,Hach Company, Inc., GE Analytical
Instruments, Inc., Teledyne Analytical Instruments, Mettler-Toledo
International Inc., and Analytik Jena AG. These players are focusing on new
product launches and collaborations to expand their market share.
The increasing prevalence of genetic abnormalities and various cancers presents
numerous growth opportunities in the molecular cytogenetics market.
Technological advancements are enabling molecular cytogenetics testing for
early cancer detection, disease diagnosis, prognosis, and treatment monitoring.
North America dominates the global molecular cytogenetics market owing to major
technological advancements, rapidly growing biotechnology industry, and rising
cancer burden in the region. However, Asia Pacific is expected to witness the
highest growth over the forecast period due to increasing R&D investments,
rising healthcare expenditure, and growing awareness about advanced diagnostic
techniques in emerging countries like India and China.
Market Drivers
Increasing incidence of genetic disorders and various types of cancers is a
major driver of the molecular cytogenetics market. According to the World
Health Organization, cancer is among the leading causes of death worldwide with
around 10 million new cases reported every year globally. Molecular
cytogenetics helps identify specific chromosomal abnormalities and genetic
mutations related to cancer, which aids in timely clinical diagnosis and
management.
Growing application of molecular techniques in prenatal genetic screening
during pregnancy for detection of fetal abnormalities is also fueling market
growth. Technological advancements allowing high-resolution analysis and rapid,
automated testing are further supporting the adoption of molecular cytogenetics
in clinical research and diagnostics.
Market Restraints
High costs associated with molecular cytogenetics instruments, reagents,
and testing may hinder the market growth to some extent. Additionally, lack of
skilled professionals and low awareness about these advanced testing techniques
in developing nations pose challenges to market expansion globally. Limited
reimbursement policies also restrain the adoption of molecular cytogenetics in
certain countries.
Segment Analysis
Fluorescence in situ hybridization (FISH) holds the
largest share in the molecular cytogenetics market owing to its wide
applications in cancer diagnosis and genetic disorders screening. Cancer
diagnosis diagnostic testing is dominating segment as major chunk of molecular
cytogenetics testing is carried out for cancer diagnosis and monitoring. These
tests play a crucial role in detecting various chromosomal abnormalities and
gene mutations in cancer cells that helps in determining the appropriate
treatment for cancer patients.
Global Analysis
North America is the largest and fastest growing regional market for
molecular cytogenetics. Higher adoption of advanced diagnostic technologies for
cancer and genetic disorder diagnosis along with availability of reimbursement
for molecular diagnostic tests are major factors behind its dominance. Asia
Pacific is predicted to witness highest growth during forecast period owing to
increasing healthcare expenditure, rising patient pool of genetic disorders and
cancer, growing focus of multinational companies on untapped Asian markets and
improving diagnostic infrastructure in emerging Asian countries.
Get
more insights on this topic: https://www.ukwebwire.com/molecular-cytogenetics-market-is-in-trends-by-next-generation-sequencing-technology/
Comments
Post a Comment